NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Kröger N, Gribben J, Chabannon C, et al., editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. doi: 10.1007/978-3-030-94353-0_26
The EBMT/EHA CAR-T Cell Handbook [Internet].
Show details
- Contents
< PrevNext >
Francis Ayuk Ayuketang and Ulrich Jäger.
Author Information and Affiliations
Published online: February 7, 2022.
Cytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37–93%, G3/4: 1–23%) (Neelapu et al. 2017; Schuster et al. 2019; Abramson et al. 2020).
Cytokine Release Syndrome (CRS)
Definition and Occurrence
Cytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37–93%, G3/4: 1–23%) (Neelapu et al. 2017; Schuster et al. 2019; Abramson et al. 2020).
Diagnosis
Clinical Symptoms, Laboratory Diagnosis, Differential Diagnosis, and Predictive Factors
CRS usually manifests with fever preceding or accompanied by general symptoms, such as malaise, headache, arthralgia, anorexia, rigours, and fatigue, and can rapidly progress to hypoxia, tachypnoea, tachycardia, hypotension, arrhythmia, culminating in shock cardiorespiratory organ dysfunction, and failure.
Although the diagnosis of CRS cannot be established or ruled out by laboratory diagnostics, they can be used to monitor organ dysfunction. CRS symptoms and laboratory findings closely mimic infection; therefore, infectious workup and treatment are of primary importance. Other relevant differential diagnoses include tumour lysis and progression of the underlying malignancy.
Prediction of CRS in an individual patient is not yes possible. However, some factors, such as high tumour burden and CAR-T cell dose, seem to be associated with a higher risk of CRS.
Management
Patients receiving CAR-T cells should be monitored continuously or at regular intervals for cardiovascular function and temperature. The first sign of CRS is usually fever. Mild CRS (G1) can be managed conservatively. All higher grades require intensive monitoring and intervention. Early use now recommended (Table 26.1) (Yakoub-Agha et al. 2020).
Fig. 26.1
Management of CRS—Modified according to EBMT recommendations
Table 26.1
Scoring of CRS (adapted from Yakoub-Agha et al. 2020)
Monitoring: Patients with CRS 1 can be monitored on the regular ward or Intermediate Care ward, starting from G2, and admission to an ICU should be considered.
Supportive therapy consists of fluids and antipyretics. The use of vasopressors automatically marks higher grade CRS.
Anti-Cytokines
Tocilizumab is EMA and FDA approved for the treatment of CRS. Prophylactic, preemptive or risk-adapted use may reduce the risk of severe CRS without attenuating antitumour efficacy.
(Locke et al. 2017; Caimi et al. 2020; Gardner et al. 2019; Kadauke et al. 2021). Clinical trial data on the use of siltuximab and anakinra are still lacking.
Steroids
In contrast to initial clinical studies, short courses of steroids do not seem to have detrimental effects on CAR-T cell expansion and survival or clinical outcome.
Antibiotics
Because CRS cannot be decisively differentiated from infection, most centres administer antibiotic treatment in cases of neutropenic fever. However, the use of growth factors during the first few weeks should be restricted. GM-CSF is to be avoided.
sHLH/MAS
Secondary or reactive haemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammation syndrome that occurs in the context of allo-HCT, haematological malignancies, infection, and rheumatic or autoimmune disease and is characterized by hyperactive macrophages and lymphocytes, haemophagocytosis, and multiorgan damage (Carter et al. 2019; Neelapu et al. 2018; Sandler et al. 2020). The proposed diagnostic criteria are summarized in Table 26.2. Management of sHLH generally follows similar algorithms as that for severe CRS. In refractory patients, treatment may follow the management framework proposed by Mehta et al. (2020), with a key role for anakinra.
Table 26.2
Diagnostic criteria for HLA (adapted from Neelapu et al. 2018)
Key Points
Cytokine release syndrome is a frequent complication. However, severe CRS is rare if management is proactive.
sHLH/MAS is a rare but severe complication that requires prompt recognition and intervention.
References
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52. [PubMed: 32888407] [CrossRef]
Caimi PF, Sharma A, Rojas P, et al. CAR-T therapy for lymphoma with prophylactic tocilizumab: decreased rates of severe cytokine release syndrome without excessive neurologic toxicity. Blood. 2020;136:30–1. https://ash
.confex.com /ash/2020/webprogram/Paper143114.html. [CrossRef] Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5–17. [PubMed: 29481673] [CrossRef]
Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR-T cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149–58. [PMC free article: PMC6908832] [PubMed: 31697826] [CrossRef]
Kadauke S, Myers RM, Li Y, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol. 2021;39(8):920–30. [PMC free article: PMC8462622] [PubMed: 33417474] [CrossRef]
Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic Tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130(Supplement 1):1547.
Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2(6):e358–67. [PMC free article: PMC7198216] [PubMed: 32373790] [CrossRef]
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. [PMC free article: PMC5882485] [PubMed: 29226797] [CrossRef]
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. [PMC free article: PMC6733403] [PubMed: 28925994] [CrossRef]
Sandler RD, Carter S, Kaur H, Francis S, Tattersall RS, Snowden JA. Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)-time to reappraise with modern diagnostic and treatment strategies? Bone Marrow Transplant. 2020;55(2):307–16. [PMC free article: PMC6995779] [PubMed: 31455895] [CrossRef]
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. [PubMed: 30501490] [CrossRef]
Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316. [PMC free article: PMC7012497] [PubMed: 31753925] [CrossRef]
Copyright 2022, The Author(s)
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Bookshelf ID: NBK584171PMID: 36122067DOI: 10.1007/978-3-030-94353-0_26
Contents
< PrevNext >
